Intervention

SRT501

Source-reviewedGoverned LongevityNext intelligence profile

Evidence reviewed through2026-08-07

Executive intelligence snapshot

Current reviewed view

The small Phase 2 study was terminated after 24 enrollments; safety burden and limited activity prevented a clean efficacy interpretation.

This profile includes 2 reviewed relationship(s) and 2 reviewed source(s).

This view is bounded by reviewed evidence and does not provide a recommendation or a claim beyond the stated review date.

Evidence state

Source-reviewed

Evidence reviewed through2026-08-07

Evidence state

What the evidence supports

The small Phase 2 study was terminated after 24 enrollments; safety burden and limited activity prevented a clean efficacy interpretation.

Evidence boundary

Key limitations

The registry does not establish that all resveratrol exposures or sirtuin biology fail; disease severity and combination treatment complicate causal attribution.
Does not establish efficacy, mechanism falsification, approval, utility, rejuvenation, or investment attractiveness.

Not established

Key unknowns

Dose, route, population, and outcomes not recorded in this reviewed profile remain unknown.
The reviewed evidence does not resolve this dimension beyond the recorded boundary.

Next evidence milestone

What would change this view?

No specific evidence milestone is recorded yet.

Evidence reviewed through 2026-08-07.

Intelligence connections

Linked company

Sirtris, a GSK Company

Company

Tested in

SRT501 multiple-myeloma Phase 2

Trial

Reviewed source layer

Evidence & sources

These cards show only metadata present in the reviewed source registry.

trial registry

SRT501 Alone or With Bortezomib in Multiple Myeloma

ClinicalTrials.gov

Reference: NCT00920556

Reviewed: 2026-08-06

bibliographic index

A phase 2 study of SRT501 with bortezomib in relapsed or refractory multiple myeloma

PubMed

Reference: 23205612